Literature DB >> 32325459

The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas.

Laura Annaratone1,2, Eliano Cascardi1,2, Elena Vissio1,2, Ivana Sarotto1, Ewa Chmielik3, Anna Sapino1,2, Enrico Berrino1,2, Caterina Marchiò4,5.   

Abstract

Heterogeneity in breast carcinomas can be appreciated at various levels, from morphology to molecular alterations, and there are well-known genotypic-phenotypic correlations. Clinical decision-making is strictly focused on the evaluation of tumor cells and is based on the assessment of hormone receptors and of the HER2 status, by means of a combination of immunohistochemical and in situ hybridization techniques. The tumor microenvironment (TME) also shows a multifaceted nature stemming from the different actors populating the intratumoral and the peritumoral stroma of breast carcinomas. Of note, we have now evidence that tumor-infiltrating lymphocytes (TILs) are clinically meaningful as their quantification in the intratumoral stroma strongly correlates with good prognosis, in particular in triple-negative and HER2-positive breast cancer patients. Nevertheless, TILs are just one of the many actors orchestrating the complexity of the TME, which is populated by immune and non-immune cells (cancer-associated fibroblasts, cancer-associated adipocytes), as well as non-cellular components such as chemical inflammation mediators. In this review article we will overview the main features of the distinct cell compartments by discussing (i) the potential impact the TME may have on the prognostic stratification of breast cancers and (ii) the possible predictive value of some markers in the context of immunotherapy in light of the recent results of phase III studies in advanced and early triple-negative breast cancer patients.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; Cancer-associated fibroblasts; Immune cells; Immunotherapy; Ligand 1 of programmed cell death protein 1; Mutational load; Tumor-infiltrating lymphocytes

Mesh:

Substances:

Year:  2020        PMID: 32325459      PMCID: PMC7265767          DOI: 10.1159/000507055

Source DB:  PubMed          Journal:  Pathobiology        ISSN: 1015-2008            Impact factor:   4.342


  154 in total

1.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

2.  Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice.

Authors:  Jean Albrengues; Mario A Shields; David Ng; Chun Gwon Park; Alexandra Ambrico; Morgan E Poindexter; Priya Upadhyay; Dale L Uyeminami; Arnaud Pommier; Victoria Küttner; Emilis Bružas; Laura Maiorino; Carmelita Bautista; Ellese M Carmona; Phyllis A Gimotty; Douglas T Fearon; Kenneth Chang; Scott K Lyons; Kent E Pinkerton; Lloyd C Trotman; Michael S Goldberg; Johannes T-H Yeh; Mikala Egeblad
Journal:  Science       Date:  2018-09-28       Impact factor: 47.728

3.  Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival.

Authors:  A Obermair; C Kurz; K Czerwenka; M Thoma; A Kaider; T Wagner; G Gitsch; P Sevelda
Journal:  Int J Cancer       Date:  1995-07-17       Impact factor: 7.396

4.  Interobserver Agreement Between Pathologists Assessing Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer Using Methodology Proposed by the International TILs Working Group.

Authors:  Shannon K Swisher; Yun Wu; Carlos A Castaneda; Genvieve R Lyons; Fei Yang; Coya Tapia; Xiuhong Wang; Sandro A A Casavilca; Roland Bassett; Miluska Castillo; Aysegul Sahin; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2016-03-10       Impact factor: 5.344

Review 5.  Neutrophils in cancer.

Authors:  Louise W Treffers; Ida H Hiemstra; Taco W Kuijpers; Timo K van den Berg; Hanke L Matlung
Journal:  Immunol Rev       Date:  2016-09       Impact factor: 12.988

6.  Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones.

Authors:  Yayun Liang; Rolf A Brekken; Salman M Hyder
Journal:  Endocr Relat Cancer       Date:  2006-09       Impact factor: 5.678

7.  An increased neutrophil-to-lymphocyte ratio predicts poorer survival following recurrence for patients with breast cancer.

Authors:  Toshiaki Iwase; Takafumi Sangai; Masahiro Sakakibara; Junta Sakakibara; Emi Ishigami; Shouko Hayama; Ayako Nakagawa; Takahito Masuda; Shunsuke Tabe; Takeshi Nagashima
Journal:  Mol Clin Oncol       Date:  2016-12-05

Review 8.  Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC).

Authors:  Elizabeth F Blackley; Sherene Loi
Journal:  Breast       Date:  2019-11       Impact factor: 4.380

9.  Preoperative elevated neutrophil-to-lymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis.

Authors:  Junwu Duan; Linlin Pan; Ming Yang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.889

Review 10.  Roles of the immune system in cancer: from tumor initiation to metastatic progression.

Authors:  Hugo Gonzalez; Catharina Hagerling; Zena Werb
Journal:  Genes Dev       Date:  2018-10-01       Impact factor: 11.361

View more
  21 in total

1.  The Tumor-Specific Expression of L1 Retrotransposons Independently Correlates with Time to Relapse in Hormone-Negative Breast Cancer Patients.

Authors:  Enrico Berrino; Umberto Miglio; Sara Erika Bellomo; Carla Debernardi; Alberto Bragoni; Annalisa Petrelli; Eliano Cascardi; Silvia Giordano; Filippo Montemurro; Caterina Marchiò; Tiziana Venesio; Anna Sapino
Journal:  Cells       Date:  2022-06-16       Impact factor: 7.666

2.  Peripheral Blood Mononuclear Cell Populations Correlate with Outcome in Patients with Metastatic Breast Cancer.

Authors:  Anna-Maria Larsson; Olle Nordström; Alexandra Johansson; Lisa Rydén; Karin Leandersson; Caroline Bergenfelz
Journal:  Cells       Date:  2022-05-13       Impact factor: 7.666

3.  Overcoming the Challenges of High Quality RNA Extraction from Core Needle Biopsy.

Authors:  Hanne Locy; Rohann J M Correa; Dorien Autaers; Ann Schiettecatte; Jan Jonckheere; Wim Waelput; Louise Cras; Stefanie Brock; Stefaan Verhulst; Keith Kwan; Marian Vanhoeij; Kris Thielemans; Karine Breckpot
Journal:  Biomolecules       Date:  2021-04-22

4.  Whole-Lesion Histogram Analysis of the Apparent Diffusion Coefficient as a Quantitative Imaging Biomarker for Assessing the Level of Tumor-Infiltrating Lymphocytes: Value in Molecular Subtypes of Breast Cancer.

Authors:  Wen-Jie Tang; Zhe Jin; Yan-Ling Zhang; Yun-Shi Liang; Zi-Xuan Cheng; Lei-Xin Chen; Ying-Ying Liang; Xin-Hua Wei; Qing-Cong Kong; Yuan Guo; Xin-Qing Jiang
Journal:  Front Oncol       Date:  2021-01-08       Impact factor: 6.244

5.  A strengthening the reporting of observational studies in epidemiology (STROBE): Are HE4 and CA 125 suitable to detect a Paget disease of the vulva?

Authors:  Miriam Dellino; Giulio Gargano; Raffele Tinelli; Carmine Carriero; Carla Minoia; Skrypets Tetania; Erica Silvestris; Vera Loizzi; Angelo Paradiso; Porzia Casamassima; Antonio Tufaro; Gennaro Cormio; Vito Michele Garrisi
Journal:  Medicine (Baltimore)       Date:  2021-02-05       Impact factor: 1.817

6.  Long Non-Coding RNA A2M-AS1 Promotes Breast Cancer Progression by Sponging microRNA-146b to Upregulate MUC19.

Authors:  Yuncong Liu; Qi Zhang; Jing Wu; Hanqun Zhang; Xin Li; Zhaopeng Zheng; Min Luo; Libo Li; Yang Xiang; Feiyue Yang; Li Wu
Journal:  Int J Gen Med       Date:  2020-11-27

Review 7.  The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer.

Authors:  Yiqi Fan; Shuai He
Journal:  Cancer Manag Res       Date:  2022-01-03       Impact factor: 3.989

Review 8.  Modified mesenchymal stem cells in cancer therapy: A smart weapon requiring upgrades for wider clinical applications.

Authors:  Carla Vicinanza; Elisabetta Lombardi; Francesco Da Ros; Miriam Marangon; Cristina Durante; Mario Mazzucato; Francesco Agostini
Journal:  World J Stem Cells       Date:  2022-01-26       Impact factor: 5.326

Review 9.  Importance of the origin of mesenchymal (stem) stromal cells in cancer biology: "alliance" or "war" in intercellular signals.

Authors:  Noemi Eiro; Maria Fraile; Silvia Fernández-Francos; Rosario Sánchez; Luis A Costa; Francisco J Vizoso
Journal:  Cell Biosci       Date:  2021-06-10       Impact factor: 7.133

10.  Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.

Authors:  Antonino Grassadonia; Vincenzo Graziano; Laura Iezzi; Patrizia Vici; Maddalena Barba; Laura Pizzuti; Giuseppe Cicero; Eriseld Krasniqi; Marco Mazzotta; Daniele Marinelli; Antonella Amodio; Clara Natoli; Nicola Tinari
Journal:  Cells       Date:  2021-07-03       Impact factor: 7.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.